Skip to main content

Ramon Martí Seves

Institutions of which they are part

Head of group
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Ramon Martí Seves

Institutions of which they are part

Head of group
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Projects

x

IP: Laia Perez Lasarte
Collaborators: Pau Mollá Zaragozá, Ramon Martí Seves
Funding agency: Fundació Institut de Recerca HUVH
Funding: 55810.89
Reference: VHIR/PHDPROGRAMME/2022/MOLLA
Duration: 01/06/2022 - 30/09/2025

Desarrollo de una estrategia de terapia génica para la deficiencia combinada de la fosforilación oxidativa tipo 1 debido a mutaciones en GFM1.

IP: Ramon Martí Seves
Collaborators: Desarrollo de una estrategia de terapia génica para la deficiencia combinada de la fosforilación oxidativa tipo 1 debido a mutac
Funding agency: Fundación Invest. Médica Mutua Madrileña
Funding: 150000
Reference: AP176532021
Duration: 07/07/2021 - 06/07/2025

Eficacia preclínica del uso de desoxiribonucleósidos como tratamiento para los síndromes de depleción/deleciones multiples del DNA mitocondrial (MDDS). Ampliación a causas genéticas no exploradas.

IP: Ramon Martí Seves
Collaborators: Eficacia preclínica del uso de desoxiribonucleósidos como tratamiento para los síndromes de depleción/deleciones multiples del D, Mª Jesus Melia Grimal, Javier Francisco Ramón Pasías
Funding agency: Instituto de Salud Carlos III
Funding: 153670
Reference: PI21/00554
Duration: 01/01/2022 - 31/12/2025

Deoxyribonucleosides as a therapy for mitochondrial DNA replication disorders: understanding therapeutic mechanisms and broadening the treatment to mutations in POLG and other related genes.

IP: Ramon Martí Seves
Collaborators: Yolanda Cámara Navarro, Javier Francisco Ramón Pasías
Funding agency: Fundació La Marató de TV3
Funding: 163812.5
Reference: 97/C/2020
Duration: 01/06/2021 - 31/12/2024

Related news

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The newly developed analytical workflow could in the future be introduced as a comprehensive diagnostic test for patients with mitochondrial diseases.

Related professionals

Joaquim Vives Armengol

Joaquim Vives Armengol

Main researcher
Musculoskeletal Tissue Engineering
Read more
Nuria Casalé Cabanes

Nuria Casalé Cabanes

Predoctoral researcher
Infectious Diseases
Read more
Marcos Buj Vicente

Marcos Buj Vicente

Junior researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Jaume Alijotas Reig

Jaume Alijotas Reig

Head of group
Systemic Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.